Current status of liver transplantation in children

Pediatric Clinics of North America

Volumn 50, Issue 6, 2003, Pages 1335-1374

  McDiarmid, S V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ARTERY THROMBOSIS; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CADAVER DONOR; CHILD; CLINICAL TRIAL; DIABETES MELLITUS; DRUG FATALITY; GRAFT REJECTION; GRAFT SURVIVAL; HODGKIN DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PATIENT COMPLIANCE; PATIENT SELECTION; PEDIATRICS; REVIEW; SEPSIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TRANSPLANTATION TOLERANCE;

EID: 0346365434     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(03)00150-0     Document Type: Review

References (266)

1. Goss JA, Shackleton CR, McDiarmid SV, Maggard M, Swenson K, Seu P, et al. Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg 1998;228(3):411-20.
2. Otte JB, de Ville de Goyet J, Reding R, Van Obbergh L, Veyckemans F, Carlier MA, et al. Pediatric liver transplantation: from the full-size liver graft to reduced, split, and living related liver transplantation. Pediatr Surg Int 1998;13(5-6):308-18.
3. Otte JB. History of pediatric liver transplantation: Where are we coming from? Where do we stand? Pediatr Transplant 2002;6(5):378-87.
4. Gralnek IM, Liu H, Shapiro MF, Martin P. The United States liver donor population in the 1990s. Transplantation 1999;67(7):1019-23.
5. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant data 1992-2000: 2001 annual report. Rockville: Department of Health and Human Services, Health Resources and Administration, Office of Special Programs, Division of Transplantation; Richmond (VA): United Network of Organ Sharing; Ann Arbor: University Renal Research and Education Association; 2001.
6. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62.
7. Molmenti ER, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002;8(9):736-48.
8. U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant data 1992-2000: 2001 annual report. Rockville: Department of Health and Human Services, Health Resources and Administration, Office of Special Programs, Division of Transplantation; Richmond (VA): United Network of Organ Sharing; Ann Arbor: University Renal Research and Education Association; 2001.
9. Broelsch CE, Emond JC, Thistlethwaite JR, Whitington PF, Zucker AR, Baker AL, et al. Liver transplantation, including the concept of reduced-size liver transplants in children. Ann Surg 1988;208:410-20.
10. McDiarmid S, Anand R, SPLIT Research Group. Studies of pediatric liver transplantation: 2002 update. Pediatr Transplant, in press.
11. Broelsch CE, Whitington PF, Emond JC, Heffron TG, Thistlethwaite JR, Stevens L. Liver transplantation in children from living related donors: surgical techniques and results. Ann Surg 1991;214:428-37; discussion 437-9.
12. Emond JC, Heffron TG, Kortz EO, Gonzalez-Vallina R, Contis JC, Black DD, et al. Improved results of living-related liver transplantation with routine application in a pediatric program. Transplantation 1993;55:835-40.
13. Kiuchi T, Ueomoto S, Egawa H, et al. Living donor liver transplantation in Kyoto, 2001. Clin Transplant 2001;195-201.
14. Reding R, Chardot C, Paul K, Veyckmans F, Van Obbergh L, de Clety SC, et al. Living-related liver transplantation in children at Saint-Luc University Clinics: a seven year experience in 77 recipients. Acta Chir Belg 2001;101(1):17-9.
15. Egawa H, Inomata Y, Uemoto S, et al. Biliary anastomotic complications in 400 living related liver transplantations [abstract]. World J Surg 2001;25(10):1300-7.
16. Surman OS. The ethics of partial-liver donation [abstract]. N Engl J Med 2002;346(14):1038.
17. Shaw Jr BW. Where monsters hide. Liver Transpl 2001;7(10):928-32.
18. Karliova M, Malago M, Valentin-Gamazo C, et al. Living-related liver transplantation from the view of the donor: a 1-year follow-up survey. Transplantation 2002;73(11):1799-804.
19. Strong RW. Whither living donor liver transplantation? Liver Transpl 1999;5(6):536-8.
20. Malago M, Rogiers X, Burdelski M, Broelsch CE. Living related transplantation: 36 cases at the University of Hamburg. Transplant Proc 1994;26(6):3620-1.
21. Diaz GC, Renz JF, Mudge C, et al. Donor health assessment after living-donor liver transplantation. Ann Surg 2002;236(1):120-6.
22. Renz JF, Roberts JP. Long-term complications of living donor liver transplantation. Liver Transplant 2000;6(6 Suppl 2):S73-6.
23. Shiffman ML, Brown RSJ, Olthoff KM, Everson G, Miller C, Siegler M, et al. Living donor liver transplantation: summary of a conference at the National Institutes of Health. Liver Transplant 2002;8(2):174-88.
24. de Ville de Goyet J, Hausleithner V, Reding R, Lerut J, Janssen M, Otte J-B. Impact of innovative techniques on the waiting list and results in pediatric liver transplantation. Transplantation 1993;56:1130-6.
25. de Ville de Goyet J. Split liver transplantation in Europe: 1988 to 1993. Transplantation 1995;59:1371-6.
26. Emond JC, Whitington PF, Thistlethwaite JR, Cherqui D, Alonso EA, Woodle IS, et al. Transplantation of two patients with one liver: analysis of a preliminary experience with split-liver grafting. Ann Surg 1990;212:14-22.
27. Rogiers X, Malago M, Gawad KA, Kuhlencordt R, Froschle G, Sturm E, et al. One year of experience with extended application and modified techniques of split liver transplantation. Transplantation 1996;61:1059-61.
28. Reichert PR, Renz JF, D'Albuquerque LA, Rosenthal P, Lim RC, Roberts JP, et al. Surgical anatomy of the left lateral segment as applied to living-donor and split-liver transplantation: a clinicopathologic study. Ann Surg 2000;232(5):658-64.
29. Goss JA, Yersiz H, Shackleton CR, Seu P, Smith CV, Markowitz JS, et al. In situ splitting of the cadaveric liver for transplantation. Transplantation 1997;64(6):871-7.
30. Wallot MA, Mathot M, Janssen M, et al. Long-term survival and late graft loss in pediatric liver transplant recipients: a 15-year single-center experience. Liver Transpl 2002;8(7):615-22.
31. Spada M, Gridelli B, Colledan M, Segalin A, Lucianetti A, Petz W, et al. Extensive use of split liver for pediatric liver transplantation: a single-center experience. Liver Transpl 2000;6(4):415-28.
32. Ramcharan T, Glessing B, Lake JR, Payne WD, Humar A. Outcome of other organs recovered during in situ split-liver procurements. Liver Transpl 2001;7(10):853-7.
33. Deshpande RR, Bowles MJ, Vilca-Melendez H, Srinivasan P, Girlanda R, Dhawan A, et al. Results of split liver transplantation in children. Ann Surg 2002;236(2):248-53.
34. Sieders E, Peeters PM, ten Vergert EM, Bijleveld C, de Jong KP, Zwaveling JH, et al. Analysis of survival and morbidity after pediatric liver transplantation with full-size and technical-variant grafts. Transplantation 1999;68(4):540-5.
35. Langham Jr MR, Tzakis AG, Gonzalez-Peralta R, Thompson JF, Rosen CB, Nery JR, et al. Graft survival in pediatric liver transplantation. J Pediatr Surg 2001;36(8):1205-9.
36. Ghobrial RM, Yersiz H, Farmer DG, Amersi F, Goss J, Chen P, et al. Predictors of survival after in vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg 2000;232(3):312-23.
37. Broering DC, Mueller L, Ganschow R, Kim JS, Achilles EG, Schafer H, et al. Is there still a need for living-related liver transplantation in children? Ann Surg 2001;234(6):713-22.
38. Farmer DG, Yersiz H, Ghobrial RM, McDiarmid SV, Gornbein JA, Le H, et al. Early graft function after pediatric liver transplantation: comparison between in situ split liver grafts and living-related liver grafts. Transplantation 2001;72(11):1795-802.
39. Malago M, Hertl M, Testa G, Rogiers X, Broelsch CE. Split-liver transplantation: future use of scarce donor organs. World J Surg 2002;26(2):275-82.
40. Emond JC, Heffron TG, Thistlethwaite JR. Innovative approaches to donor scarcity: a critical comparison between split liver and living related liver transplantation. Hepatology 1991;14:92.
41. Toso C, Ris F, Mentha G, Oberholzer J, Morel P, Majno P. Potential impact of in situ liver splitting on the number of available grafts. Transplantation 2002;74(2):156-7.
42. Wiesenhaan-Stellingwerff GC, Smits JMA, de Boer J, et al. Pediatric liver transplantation: 10 years Eurotransplant experience [abstract]. Pediatr Transplant 2000;4(2):124.
43. Sindhi R, Rosendale J, Mundy D, Taranto S, Baliga P, Reuben A, et al. Impact of segmental grafts on pediatric liver transplantation: a review of the United Network for Organ Sharing Scientific Registry data (1990-1996). J Pediatr Surg 1999;34(1):107-10.
44. Emond JC, Freeman Jr RB, Renz JF, Yersiz H, Rogiers X, Busuttil RW. Optimizing the use of donated cadaveric livers: analysis and policy development to increase the application of split-liver transplantation. Liver Transpl 2002;8(10):863-72.
45. de Ville de Goyet J, Chen CL, Chen YS, Wang CC, Wang SH, Chiang YC, et al. International sharing of split liver grafts in Asia: initial experience. Clin Transplant 2000;14(4 Pt 1):355-9.
46. Committee on Organ Procurement and Transplantation Policy. Organ procurement and transplantation: Assessing current policies and potential impact of the DHHS final rule. Washington, DC: National Academy Press; 1999.
47. Freeman Jr RB, Edwards EB. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000;6(5):543-52.
48. Wiesner RH, McDiarmid SV, Kamath PS, Edward EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7(7):567-80.
49. McDiarmid SV, Anand R, Lindblad A. Development of a pediatric end stage liver disease score to predict poor outcome awaiting liver transplantation. Transplantation 2002;74(2):173-81.
50. Mazariegos GV, Anand R, McDiarmid SV. Validation of PELD severity score in a pediatric transplant candidate database [abstract]. Am J Transplant 2002;2(3):251.
51. McDiarmid SV, Davies DB, Edwards EB. Improved graft survival of pediatric liver recipients transplanted with pediatric-aged liver donors. Transplantation 2000;70(9):1283-91.
52. Yasutomi M, Harmsmen S, Innocenti F, DeSouza N, Krom RAF. Outcome of the use of pediatric donor livers in adult recipients. Liver Transpl 2001;7(1):48-40.
53. McDiarmid S. How can we optimize the outcome of liver grafts from pediatric donors? Liver Transpl 2001;7(1):48-50.
54. Atkison PR, Ross BC, Williams S, et al. Long-term results of pediatric liver transplantation in a combined pediatric and adult transplant program. CMAJ 2002;166(13):1663-71.
55. Reding R, Gennari F, Janssen M, Jamart J, de Ville de Goyet J, Lerut J, et al. The pediatric liver transplant program at the Universite Catholique de Louvain, Cliniques Saint-Luc, Brussels: overall results in 444 children (1984-1997). Acta Gastroenterol Belg 1999;62:285-9.
56. Tzakis AG, Gordon RD, Shaw BWJ, Iwatsuki S, Starzl TE. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation 1985;40:667-71.
57. Rela M, Muiesan P, Bhatnagar V, Baker A, Mowat AP, Mieli-Vergani G, et al. Hepatic artery thrombosis after liver transplantation in children under 5 years of age. Transplantation 1996;61:1355-7.
58. Stringer MD, Marshall MM, Muiesan P, Karani JB, Kane PA, Mieli-Vergani G, et al. Survival and outcome after hepatic artery thrombosis complicating pediatric liver transplantation. J Pediatr Surg 2001;36(6):888-91.
59. Inomoto T, Nishizawa F, Sasaki H, Terajima H, Shirakata Y, Miyamoto S, et al. Experiences of 120 microsurgical reconstructions of hepatic artery in living related liver transplantation. Surgery 1996;119:20-6.
60. Mazzaferro V, Esquivel CO, Makowka L, Kahn D, Belle S, Scantlebury VP, et al. Factors responsible for hepatic artery thrombosis after pediatric liver transplantation. Transplant Proc 1989;21:2466-7.
61. Mazzaferro V, Esquivel CO, Makowka L, Belle S, Kahn D, Koneru B, et al. Hepatic artery thrombosis after pediatric liver transplantation: a medical or surgical event? Transplantation 1989;47:971-7.
62. Busuttil RW, Seu P, Millis JM, Olthoff KM, Hiatt JR, Milewicz A, et al. Liver transplantation in children. Ann Surg 1991;213:48-57.
63. Jennings I, Calne RY, Baglin TP. Predictive value of Von Willebrand factor to ristocetin cofactor ratio and thrombin-antithrombin complex levels for hepatic vessel thrombosis and graft rejection after liver transplantation. Transplantation 1994;57:1046-51.
64. Hashikura Y, Kawasaki S, Okumura N, Ishikawa S, Matsunami H, Ikegami T, et al. Prevention of hepatic artery thrombosis in pediatric liver transplantation. Transplantation 1995;60:1109-12.
65. Pastacaldi S, Teixeira R, Montalto P, et al. Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpl 2001;7(2):75-81.
66. Shaked A, Vargas J, Csete ME, Kiai K, Jurim O, Colquhoun S, et al. Diagnosis and treatment of bowel perforation following pediatric orthotopic liver transplantation. Arch Surg 1994;128:994-9.
67. SPLIT Research Group. Studies of pediatric liver transplantation (SPLIT): year 2000 outcomes. Transplantation 2001;72(3):463-76.
68. Cacciarelli TV, Dvorchik I, Mazariegos G, et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients primary tacrolimus (FK506) therapy. Transplantation 1999;68(5):650-5.
69. McDiarmid S, Anand R, SPLIT Research Group. A multivariate analysis of factors effecting patient and graft survival after pediatric transplantation. Am J Transplant 2003;3:307.
70. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997;64(12):1801-7.
71. Sudan DL, Shaw BWJ, Langnas AN. Causes of late mortality in pediatric liver transplant recipients. Ann Surg 1998;227:289-95.
72. Ryckman FC, Alonso MH, Bucuvalas JC, Balistreri WF. Long-term survival after liver transplantation. J Pediatr Surg 1999;34(5):845-9.
73. Fridell JA, Jain A, Reyes J, et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. Transplantation 2002;74(12):1721-4.
74. McDiarmid S, Busuttil RW, Goss J, et al. Causes of late graft dysfunction, re-transplantation (RE-TX) and death after pediatric (OLT) orthotopic liver transplantation [abstract]. Liver Transpl Surg 1997;3(5):C-47.
75. McDiarmid SV, Busuttil RW, Ascher NL, Burdick JF, D'Alessandro AM, Esquivel C, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Transplantation 1995;59:530-6.
76. Kelly D, Jara P, Rodeck B, et al. Tacrolimus dual therapy versus cyclosporine-microemulsion triple therapy in paediatric liver transplantation: results from a multicentre randomized trial [abstract]. Am J Transplant 2002;2(Suppl 3):351.
77. Jain A, Mazariegos G, Kashyap R, et al. Pediatric liver transplantation: a single center experience spanning 20 years [abstract]. Transplantation 2002;73(6):941-7.
78. Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation [abstract]. Transplantation 2000;70(4):617-25.
79. Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, et al. Long-term outcomes in pediatric liver recipients: comparisons between cyclosporin A and tacrolimus. Pediatr Transplant 1999;3:22-6.
80. McDiarmid SV, Anand R. Outcome of cyclosporine and tacrolimus treated pediatric patients enrolled in the SPLIT registry [abstract]. Transplantation 2000;69(8):388.
81. Reding R. Steroid withdrawal in liver transplantation. Transplantation 2000;70(3):405-10.
82. Moukarzel AA, Najm I, Vargas JV, McDiarmid SV, Busuttil RW, Ament ME. Prediction of long-term linear growth following liver transplantation. Transplant Proc 1990;22:1558-9.
83. Chin SE, Shepherd RW, Cleghorn GJ, Patrick MK, Javorsky G, Frangoulis E, et al. Survival, growth and quality of life in children after orthotopic liver transplantation: a 5 year experience. J Pediatr Child Health 1991;27:380-5.
84. Sarna S, Laine J, Sipila I, Koistinen R, Holmberg C. Differences in linear growth and cortisol production between liver and renal transplant recipients on similar immunosuppression. Transplantation 1995;60:656-61.
85. Sarna S, Sipila I, Vihervuori E, Koistinen R, Holmberg C. Growth delay after liver transplantation in childhood: studies of underlying mechanisms. Pediatr Res 1995;38:366-72.
86. McDiarmid SV, Farmer DA, Goldstein LI, Martin P, Vargas J, Tipton JR, et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995;60:1443-50.
87. Margarit C, Martinez-Ibanez V, Tormo R, Infante D, Iglesias H. Maintenance immunosuppression without steroids in pediatric liver transplantation. Transplant Proc 1989;21:2230-1.
88. Superina R, Acal L, Bilik R, Zaki A. Growth in children after liver transplantation on cyclosporine alone or in combination with low-dose azathioprine. Transplant Proc 1993;25:2580.
89. Dunn SP, Falkenstein K, Lawrence JP, Meyers R, Vinocur CD, Billmire DF, et al. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Transplantation 1994;57:544-7.
90. Dmitrewski J, Ayres S, Gunson BK, et al. Steroid withdrawal 3 months after liver transplantation: does FK506 confer any advantages over cyclosporine? Transpl Int 1994;7(Suppl 1):S85-7.
91. Washburn K, Speeg KV, Esterl R, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72(10):1675-9.
92. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997;64:1755-60.
93. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001;7(8):693-7.
94. Birnbaum AH, Benkov KJ, Pittman NS, McFarlane-Ferreira Y, Rosh JR, LeLeiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997;25:20-5.
95. Alonso EM, Piper JB, Echols G, Thistlethwaite JR, Whitington PF. Allograft rejection in pediatric recipients of living related liver transplants. Hepatology 1996;23:40-3.
96. Murphy MS, Harrison R, Davies P, Buckels JA, Mayer AD, Hubscher S, et al. Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy. Arch Dis Child 1996;75:502-6.
97. D'Antiga L, Dhawan A, Portman B, Francavilla R, Rela M, Heaton N, et al. Late cellular rejection in pediatric liver transplantation: aetiology and outcome. Transplantation 2002;73(1):80-4.
98. Anand AC, Hubscher SG, Gunson BK, McMaster P, Neuberger JM. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995;60:1098-103.
99. Allen KJ, Rand EB, Hart J, Whitington PF. Prognostic implications of centrilobular necrosis in pediatric liver transplant recipients. Transplantation 1998;65:692-8.
100. Krasinskas AM, Ruchelli ED, Rand EB, et al. Central venulitis in pediatric liver allografts. Hepatology 2001;33(5):1141-7.
101. Sellers M, Singer A, Maller E, Olthoff K, Jacobowski D, Shaked A. Incidence of late acute rejection and progression to chronic rejection in pediatric liver recipients. Transplant Proc 1997;29:428-9.
102. Gao Z, McAllister VC, Williams GM. The "privileged" liver and hepatic tolerogenicity: repopulation of liver endothelium by bone-marrow-derived cells. Liver Transpl 2001;7(10): 918-20.
103. Dousset B, Conti F, Cherruau B, et al. Is acute rejection deleterious to long-term liver allograft function? J Hepatol 1998;29(4):660-8.
104. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28(3): 638-45.
105. McDiarmid S, Anand R, SPLIT Research Group. Immunosuppression, rejection and the effect on outcome in children after liver transplantation. Liver Transpl 2003;9:1-47.
106. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998;339(26):1905-13.
107. Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001;7(7):623-30.
108. Jain A, Mazariegos G, Pokharna R, et al. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc 2002;34(5):1968-9.
109. Gupta P, Hart J, Cronin D, Kelly S, Millis M, Brady L. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001;72(6):1098-102.
110. Kelly DA. The use of anti-interleukin-2 receptor antibodies in pediatric liver transplantation. Pediatr Transplant 2001;5:386-9.
111. Ganschow R, Broering DC, Stuerenburg I, et al. First experience with basiliximab in pediatric liver graft recipients [abstract]. Pediatr Transplant 2001;5:353-8.
112. Heffron TG, Pillen T, Smallwood GA, et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. Transplant Proc 2001;33(1-2):1449.
113. Arora N, McKiernan PJ, Beath SV, deVille de Goyet J, Kelly DA. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation. Pediatr Transplant 2002;6:214-8.
114. Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999;68(8):1195-209.
115. Sarwal MN, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72(1):13-21.
116. Birkeland SA, Larsen K-G, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998;12:87-92.
117. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001;7(6): 473-84.
118. Kahan BD. The potential role of rapamycin in pediatric transplantation as observed from adult studies. Pediatr Transplant 1999;3:175-80.
119. Wiesner R, Klintmalm G, McDiarmid S, et al. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients [abstract]. Am J Transplant 2002;2(Suppl 3):464.
120. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001;7(8):701-8.
121. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001;7(4):343-51.
122. Sindhi R, Ganjoo J, McGhee W, et al. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. Transplant Proc 2002;34:1972-3.
123. Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001;72(5):851-5.
124. Renz JF, Rosenthal P, Frankel W, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Pediatr Transplant 1998;2(1):91.
125. Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte J-B, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001;71(2): 224-9.
126. Freise CE, Hebert M, Osorio RW, Nikolai B, Lake JR, Kauffman RS, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993;25:1758-9.
127. Kovarik JM, Gridelli BG, Martin S, et al. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr Transplant 2002;6(3):224-30.
128. MacFarlane GD, Venkataramanan R, McDiarmid SV, Pirsch JD, Scheller DG, Ersfeld DL, et al. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. Pediatr Transplant 2001;5(2):119-24.
129. Sindhi R, Webber S, Goyal J, et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. Transplant Proc 2002;34:1960.
130. Dunn S, Cooney G, Sommerauer J, Lindsay C, McDiarmid S, Wong RL, et al. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients. Transplantation 1997;63:1762-7.
131. McDiarmid SV, Colonna JO, Shaked A, Vargas JH, Ament ME, Busuttil RW. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation 1993;55:1328-32.
132. Jain A, Fung JJ, Venkataramanan R, Tzakis A, Abu-Elmagd K, Alessiani M, et al. Comparative study of cyclosporine and FK506 dosage requirement in adult and pediatric orthotopic liver transplantation. Transplant Proc 1991;23:2763-6.
133. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2001;72(6): 1056-61.
134. Mazariegos GV, Reyes J, Marino IO, Demetrius AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant patients. Transplantation 1997;63:243-9.
135. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72(3):449-54.
136. nd edition. Mt. Laurel (NJ): American Society of Transplantation; 2001. p. 34-42.
137. Bishop GA, McCaughan GW. Immune activation is required for the induction of liver allograft tolerance: implications for immunosuppressive therapy. Liver Transpl 2001;7(3): 161-72.
138. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFKB: indications for tolerance induction. Transplantation 2000;70(3):415-9.
139. Sharland A, Yan Y, Wang C, Bowen DG, Sun J, Ross Sheil AG, et al. Evidence that apoptosis of activated T cells occurs in spontaneous tolerance of liver allografts and is blocked by manipulations which break tolerance. Transplantation 1999;68(11):1736-45.
140. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ilstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993;17(6):1127-52.
141. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997;64(5):709-16.
142. Cheung ST, Tsui TY, Wang WL, Yang ZF, Wong SY, Ip YC, et al. Liver as an ideal target for gene therapy: expression of CTLA4Ig by retroviral gene transfer. J Gastroenterol Hepatol 2002;17(9):1008-14.
143. Sho M, Sandner SE, Najafian N, Salama AD, Dong V, Yamada A, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002;236(5):667-75.
144. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997;64:716-20.
145. Gladdy RA, Richardson SE, Davies HD, Superina RA. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 1999;5(1):16-24.
146. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002;74(5):688-95.
147. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002;73(1):63-7.
148. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003;51(2):313-6.
149. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4(1):25-30.
150. Tollemar J, Klingspor L, Ringden O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect 2001;7(Suppl 2): 68-79.
151. Green M. Viral infections and pediatric liver transplantation. Pediatr Transplant 2002;6(1): 20-4.
152. Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Wood RP, Langnas AN, et al. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 1991;51:90-7.
153. Mellon A, Shepherd RW, Faoagali JL, Balderson G, Ong TH, Patrick M, et al. Cytomegalovirus infection after liver transplantation in children. J Gastroenterol Hepatol 1993;8:540-4.
154. King SM, Superina R, Andrews W, Winston DJ, Dunn S, Busuttil RW, et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 1997;25(5):1173-9.
155. Norris S, Kosar Y, Donaldson N, Smith HM, Zolfino T, O'Grady JG, et al. Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection. Transplantation 2002;74(4):527-31.
156. Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000;2(3):112-7.
157. Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgrom ML, Filo RS. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin Transplant 1997;11:613-7.
158. Koneru B, Jaffe R, Esquivel CO, Kunz R, Todo S, Iwatsuki S, et al. Adenoviral infections in pediatric liver transplant recipients. JAMA 1987;258:489-92.
159. Breinig MK, Zitelli B, Starzl TE. Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 1987;156:273-9.
160. Humar A, Kumar D, Caliendo AM, Moussa G, Ashi-Sulaiman A, Levy G, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002;73(4): 599-604.
161. Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002;8(8):651-8.
162. DesJardin JA, Cho E, Supran S, Gibbons L, Werner BG, Snydman DR. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. Clin Infect Dis 2001;33(8):1358-62.
163. Lautenschlager I, Lappalainen M, Linnavuori K, Suni J, Hockerstedt K. CMV infection is usually associated with concurrent HHV-6 and HHV-7 antigenemia in liver transplant patients. J Clin Virol 2002;25(Suppl 2):S57-61.
164. Evans HM, MeKiernan PJ, Beath SV, et al. Progressive liver pathology in long term survivors of paediatric liver transplantation [abstract]. Hepatology 2001;34:246A.
165. Peeters PMJG, Sieders E, Heuvel M, Bijleveld CMA, de Jong KP, ten Vergert EM, et al. Predictive factors for portal fibrosis in pediatric liver transplant recipients. Transplantation 2000;70(11):1581-7.
166. Rosenthal P, Emond JC, Heyman MB, Snyder J, Roberts J, Ascher N, et al. Pathological changes in yearly protocol liver biopsy specimens from healthy
167. McDiarmid SV. Late liver graft dysfunction. Graft 1999;2(Suppl 2):S86-94.
168. Hernandez E, McDiarmid S, Vargas J, et al. De-novo autoimmune and non-autoimmune hepatitis are important causes of late liver graft dysfunction in children [abstract]. Pediatr Transplant 2000;4(93):152-3.
169. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PI, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13.
170. Petz W, Sonzogni A, Bertani A, Spada A, Lucianetti A, Colledan M, et al. A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis. Transplant Proc 2002;34:1958-9.
171. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001;71(5):664-8.
172. Hernandez HM, Kovarik P, Whitington PF, et al. Autoimmune hepatitis as a late complication of liver transplantation [abstract]. JPGN 2001;32(2):131-6.
173. Andries S, Casamayou L, Sempoux C, Burlet M, Reding R, Otte JB, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001;72(2):267-72.
174. Harihara Y, Makuuchi M, Kawarasaki H, Takayama T, Kubota K, Hirata M, et al. Portal venoplasty for recipients in living-related liver transplantation. Transplantation 1999;68(8): 1199-200.
175. McDiarmid SV, Conrad A, Ament ME, Vargas J, Martin MG, Goss JA, et al. De novo hepatitis C in children after liver transplantation. Transplantation 1998;66:311-8.
176. Pastore M, Willems M, Cornu C, Buts JP, Reding R, de Ville de Goyet J, et al. Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation. Arch Dis Child 1995;72:403-7.
177. Dussaix E, de Paillette L, Laurent-Puig P, Martres P, Lykavieris P, Bernard O, et al. Hepatitis C virus infection in pediatric liver transplantation. Transplantation 1993;55:795-8.
178. Nowicki MJ, Ahmad N, Heubi JE, Kuramoto IK, Baroudy BM, Balistreri WF. The prevalence of hepatitis C virus (HCV) in infants and children after liver transplantation. Dig Dis Sci 1994;39(10):2250-4.
179. Gane E. Treatment for recurrent hepatitis C. Liver Transpl 2002;8(10 Suppl 1):S28-37.
180. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8(10 Suppl 1): S14-8.
181. Neuberger J. Recurrence of primary, biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl Surg 1995;1:109-15.
182. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68(2):253-6.
183. Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987;93:148-56.
184. Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RA, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg 1997;3:359-64.
185. Bahar RJ, Yanni GS, Martin MG, McDiarmid SV, Vargas JH, Gershman GB, et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 2001;72(5):829-33.
186. Reyes J, Carr B, Dvorchik I, Kocoshis S, Jaffe R, Gerber D, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 2000;136(6):795-804.
187. Al-Qabandi W, Jenkinson HC, Buckels JA, Mayer AD, Mckiernan P, Morland B, et al. Orthotopic liver transplantation for unresectable hepatoblastoma: a single center's experience. J Pediatr Surg 1999;34(8):1261-4.
188. Otte J-B, Aronson D, Vraux H, de Ville de Goyet J, Reding R, Ninane J, et al. Preoperative chemotherapy, major liver resection, and transplantation for primary malignancies in children. Transplant Proc 1996;28(4):2393-4.
189. Koneru B, Flye MW, Busuttil RW, Shaw BW, Lorber MI, Emond JC, et al. Liver transplantation for hepatoblastoma: the American experience. Ann Surg 1991;213:118-21.
190. McDiarmid SV, Farmer DG, Moore T, et al. Is resection for hepatoblastoma prior to liver transplantation detrimental to outcome? [Abstract] Liver Transpl 2002;8(6):C-65.
191. Molmenti EP, Wilkinson K, Molmenti H, Roden JS, Squires RH, Fasola CG, et al. Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. Am J Transplant 2002;2:535-8.
192. Srinivasan P, McCall J, Pritchard J, Dhawan A, Baker A, Mieli-Vergani G, et al. Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation 2002;74(5):652-5.
193. Czauderna P, Mackinlav G, Perilongo G, Brown J, Shafford E, Aronson D, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology Group. J Clin Oncol 2002;20(12):2798-804.
194. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systemic review. Liver Transpl Surg 1999;5(2):91-5.
195. Shapiro R, Weismann I, Mandel H, Eisenstein B, Ben-Ari Z, Bar-Nathan N, et al. Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children. Transplantation 2001;72(3):428-32.
196. McDiarmid SV, Colonna JO, Shaked A, Ament ME, Busuttil RW. A comparison of renal function in cyclosporine and FK506 treated patients after primary orthotopic liver transplantation. Transplantation 1993;56:847-53.
197. Fung JJ, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991;23:2977-83.
198. Laine J, Krogerus L, Fyhrquist F, Jalanko H, Ronnholm K, Holmberg C. Renal function and histopathologic changes in children after liver transplantation. J Pediatr 1994;125:863-9.
199. Bartosh SM, Alonso EM, Whitington PF. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997;11(5):354-60.
200. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986;8:332-7.
201. Walser M, Drew HH, LaFrance ND. Creatinine measurements often yield false estimates of progression in chronic renal failure. Kidney Int 1988;34:412-8.
202. Davies JG, Taylor CM, White RHR, Marshall T. Clinical limitations of the estimation of glomerular filtration rate from height/plasma creatinine ratio: a comparison with simultaneous 51Cr edetic acid slope clearance. Arch Dis Child 1982;57:607-10.
203. McDiarmid SV, Ettenger RB, Fine RN, Busuttil RW, Ament ME. Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine. Transplantation 1989;47:314-8.
204. Berg UB, Ericzon BG, Nemeth A. Renal function before and long after liver transplantation in children. Transplantation 2001;72(4):631-7.
205. Evans GO, Griffiths PD. Limitations concerning the use in children of the relationship between plasma creatinine and body height to derive glomerular filtration rate. Ann Clin Biochem 1981;18:295-8.
206. Waller DG, Keast CM, Fleming JS, Ackery DM. Measurement of glomerular filtration rate with technetium-99m DTPA: comparison of plasma clearance techniques. J Nucl Med 1987;28:372-7.
207. McDiarmid SV, Ettenger RB, Hawkins RA, Senguttvan P, Busuttil RW, Vargas JV, et al. The impairment of true glomerular filtration rate in long-term cyclosporine-treated pediatric allograft recipients. Transplantation 1990;49:81-5.
208. Chapman JR, Griffiths D, Harding NGL, Morris PJ. Reversibility of cyclosporine nephrotoxicity after three months treatment. Lancet 1985;1:125-30.
209. Wheatley HC, Datzman M, Williams JW, Miles DE, Hatch FE. Long term effects of cyclosporine on renal function in liver transplant recipients. Transplantation 1987;43:641-7.
210. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001;72(12):1934-9.
211. Marsden CD. Wilson's disease. Q J Med 1987;65:959-66.
212. Aw MM, Samaroo B, Baker AJ, Verma A, Rela M, Heaton ND, et al. Calcineurin-inhibitor related nephrotoxicity-reversability in paediatric liver transplant recipients. Transplantation 2001;72(4):746-9.
213. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low incidence of posttransplant lymphoproliferative disease in children with low-dose immunosuppression after liver transplantation. Transplant Proc 2002;34:1961-2.
214. Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000;70(1):94-9.
215. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW, Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995;60:1357-60.
216. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991;23:1101-3.
217. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krams SM, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
218. Alfrey EJ, Friedman AL, Grossman RA, Perloff LJ, Naji A, Barker CF, et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation 1992;54:250-3.
219. Rustgi VK. Epstein-Barr viral infection and posttransplantation lymphoproliferative disorders. Liver Transpl Surg 1995;1(5):100-8.
220. Sokol EM, Caragiozoglou T, Lamy M, Reding R, Otte JB. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993;56:1394-8.
221. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-27.
222. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:214-21.
223. Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998;66(8):1047-52.
224. Smets F, Vajro P, Cornu C, Reding R, Otte JB, Sokal E. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000;69(5):982-4.
225. McDiarmid SV, Jordan S, Lee GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66(12):1604-11.
226. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002;236(4): 429-37.
227. Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996;62(3): 370-5.
228. Malatack JJ, Gartner JC, Urbach AH, Zitelli BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991;118:667-75.
229. Cacciarelli TV, Green M, Jaffe R, et al. Management of post-transplant lymphoproliferative disorder (PTLD) in pediatric liver transplant recipients receiving primary tacrolimus (FK 506) therapy [abstract]. Liver Transpl Surg 1997;3(5):C-47.
230. McDiarmid S, Goss J, Seu P, Shackleton C, Vargas J, Ament M, et al. One hundred children treated with tacrolimus after primary orthotopic liver transplantation. Transplant Proc 1998;30:1397-8.
231. Wagner H-J, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002;74(5):656-64.
232. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
233. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-22.
234. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995;60:547-54.
235. Allen U, Hebert D, Petric M, Tellier R, Tran D, Superina R, et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis 2001;33:145-50.
236. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow-up and outcome. Transplantation 2002;74(3):367-72.
237. Hopwood PA, Brooks L, Parratt R, Hunt BJ, Maria B, Alero TJ, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002;74(2):194-202.
238. Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001;72(6):1078-86.
239. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002;100(12):4059-66.
240. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of post-transplant lymphoproliferative disease. Transplantation 2002;73(10):1603-10.
241. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997;157:218-22.
242. Dotti G, Rambaldi A, Fiocchi R, Motta T, Torre G, Viero P, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001;86(6):618-23.
243. Zompi S, Tulliez M, Conti F, Leblond V, Gaulard P, Blanche P, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. J Hepatol 2000;32(3): 521-7.
244. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001;345(13):1000.
245. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, et al. Generation of EBV-specific CD4 + cytotoxic T cells from virus naive individuals. J Immunol 2002;168(2):909-18.
246. Lee ES, Locker J, Nalesnik M, Reyes J, Jaffe R, Alashari M, et al. The association of Epstein-Barr virus with smooth-muscle tumors. N Engl J Med 1995;332:19-25.
247. Timmons CF, Dawson DB, Richards CS, Andrews WS, Katz JA. Epstein-Barr virus-associated leiomyosarcomas in liver transplantation recipients: origin from either donor or recipient tissue. Cancer 1999;76(8):1481-9.
248. Yokois NU, Perlman EJ, Colombani P, Wise B, Schwarz KB. Kaposi's sarcoma presenting as a protracted multisystem illness in an adolescent liver transplant recipient. Liver Transpl Surg 1997;3(5):541-4.
249. Danhaive O, Ninane J, Sokal E, Latinne D, Philippe M, Gosseye S, et al. Hepatic localization of a fibrosarcoma in a child with a liver transplant. J Pediatr 1992;120(3):434-7.
250. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001;7(11 Suppl 1):S109-18.
251. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66(9):1193-200.
252. Lopez OL, Martinez AJ, Torre-Cisneros J. Neuropathologic findings in liver transplantation: a comparative study. Transplant Proc 1991;23:3181-2.
253. Mueller AR, Platz KP, Bechstein WO, Schattenfroh N, Stoltenburg-Didinger G, Blumhardt G, et al. Neurotoxicity after orthotopic liver transplantation: a comparison between cyclosporine and FK506. Transplantation 1994;58:155-70.
254. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDRI) gene. Transplantation 2002;74(4):571-2.
255. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73(6):901-6.
256. McDiarmid SV, Gornbein JA, Fortunat M, Saikali D, Vargas JH, Busuttil RW, et al. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992;53:109-15.
257. Stewart S, Hiltebeitel C, Nici J, Waller DA, Uauy R, Andrews W. Neuropsychological outcome of pediatric liver transplantation. Pediatrics 1991;87:367-76.
258. Wayman KI, Cox KL, Esquivel CO. Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr 1997;131(6):894-8.
259. Zitelli BJ, Miller JW, Gartner Jr C, Malatack JJ, Urbach A, Belle SH, et al. Changes in life-style after liver transplantation. Pediatrics 1988;82:173-80.
260. van Mourik ID, Beath SV, Brook GA, et al. Long-term nutritional and neurodevelopmental outcome of liver transplantation in infants aged less than 12 months [abstract]. JPGN 2000;30(3):269-75.
261. DeBolt AJ, Stewart SM, Kennard BD, Petrik K, Andrews WS. A survey of psychosocial adaptation in long-term survivors of pediatric liver transplants. Child Health Care 1995;24:79-96.
262. Tornqvist J, Van Broeck N, Finkenauer C, Rosati R, Schwering K-L, Hayez J-Y, et al. Long-term psychosocial adjustment following pediatric liver transplantation. Pediatr Transplant 1999;3:115-25.
263. Schwering KL, Febo-Mandl F, Finkenauer C, Rime B, Hayez JY, Otte JB. Psychological and social adjustment after pediatric liver transplantation as a function of age at surgery and of time elapsed since transplantation. Pediatr Transplant 1997;1(2):99-100.
264. Midgley DE, Bradlee TA, Donohoe C, Kent KP, Alonso EM. Health-related quality of life in long-term survivors of pediatric liver transplantation. Liver Transpl 2000;6(3):333-9.
265. Bucuvalas JC, Britto M, Krug S, Ryckman FC, Atherton H, Alonso MP, et al. Health-related quality of life in pediatric liver transplant recipients: a single-center study. Liver Transpl 2003;9(1):62-71.
266. Asonuma K, Inomata Y, Uemoto S, Egawa H, Kiuchi T, Okajima H, et al. Growth and quality of life after living-related liver transplantation in children. Pediatr Transplant 1998;2(1):64-9.